| 101301-0 |
Views 2 && Views AP + lateral |
Find |
Chest>Spine.thoracic && Abdomen |
Pt |
Doc |
XR |
|
ACTIVE |
XR Thoracic spine Views 2 and Abdomen AP and Lateral |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
RAD |
|
101301-0 |
|
XR |
|
|
Both |
|
|
|
0 |
XR T Spine 2V + Abd Views AP+Lat |
|
|
|
N |
|
2V; 2V + Views; 2V + Views AP+Lat; 2V+(Views; 2VW; Abd; Abdo; Abdomen+; Abdominal; Anterio-Posterior; Anteroposterior; AP+Lat; CXR; Document; Dorsal spine; Films; Finding; Findings; II; Imaging; Lat; Plain Films; Point in time; Radiology; Random; Spinal; Spinal Cord; T Spine+Ab; Th/sp; Thorax; T-spine; View; Views & AP KUB; Views (AP; Views AP KUB & lateral; Views+AP; VWS; Xray; X-ray |
2.74 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101302-8 |
Leptospira sp DNA |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Leptospira sp DNA [Presence] in Blood by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101302-8 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
Leptospira DNA Bld Ql NAA+non-probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Leptospirosis; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; species; spp; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101303-6 |
Chikungunya virus RNA |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Chikungunya virus RNA [Presence] in Blood by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101303-6 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
CHIKV RNA Bld Ql NAA+non-probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; CHIKV; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101304-4 |
Dengue virus 1+2+3+4 RNA |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Dengue virus 1+2+3+4 RNA [Presence] in Blood by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101304-4 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
DENV1+2+3+4 RNA Bld Ql NAA+non-probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Breakbone fever; Dengue fever; Dengue type I; Dengue type I+II+III+IV; Denv; DENV 1+2+3+4; DENV 1+2+3+4 RNA; DENV1; DENV1+2+3+4; DNA NUCLEIC ACID PROBE; DNA probe; Flavivirus; i; II; III; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Ribonucleic acid; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101305-1 |
Plasmodium sp DNA |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Plasmodium sp DNA [Presence] in Blood by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101305-1 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
Plasmodium DNA Bld Ql NAA+non-probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Malaria; Malarial; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; PCR; Plasmodium DNA; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; species; spp; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101306-9 |
Plasmodium falciparum DNA |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Plasmodium falciparum DNA [Presence] in Blood by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101306-9 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
P falciparum DNA Bld Ql NAA+non-probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Malaria; Malarial; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; P falciparum; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101307-7 |
Plasmodium vivax+ovale DNA |
PrThr |
Bld |
Pt |
Ord |
Non-probe.amp.tar |
|
ACTIVE |
Plasmodium vivax+ovale DNA [Presence] in Blood by NAA with non-probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
101307-7 |
|
Non-probe.amp.tar |
|
|
Both |
|
|
|
0 |
P vivax+ovale DNA Bld Ql NAA+non-probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Blood; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Malaria; Malarial; Microbiology; NAA+non-probe; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; P vivax; P vivax+ovale; P vivax+ovale DNA; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Strand Displacement Amplification; TMA; Transcription mediated amplification; WB; Whole blood |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101308-5 |
Glucose post arginine stimulation panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Glucose post arginine stimulation panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
101308-5 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose p arginine stim panel SerPl |
|
|
|
N |
|
After; Arg; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose p arginine stim panel; Glucose tolerance; Glucoseur; GTT; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; PST; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Stim |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101309-3 |
Glucose^2H post dose arginine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --2 hours post dose arginine |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
101309-3 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 2h p Arg SerPl-mCnc |
|
|
|
N |
|
120 min; 120 minutes; 120min; 2 hours; 2h p Arg; After; Arg; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.74 |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 10131-1 |
T' wave amplitude.lead AVL |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
T' wave amplitude in lead AVL |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
10131-1 |
|
EKG |
|
|
Observation |
|
|
|
0 |
T' wave Amp L-AVL |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; T prime; T' wave Amp L-AVL; T wave Amp L-AVL; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 101310-1 |
Somatotropin post insulin stimulation panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Somatotropin post insulin stimulation panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
101310-1 |
|
|
|
|
Order |
|
|
|
0 |
Somatotropin p insulin stim panel SerPl |
|
|
|
N |
|
After; CHEMISTRY.CHALLENGE TESTING; GH; Growth hormone; HGH; HUM; Human growth hormone; Humulin; IH7; Insul; Lente; NPH; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; PST; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; Somatotropic hormone; Somatotropin p insulin stim panel; SR; STH; Stim; Ultralente |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101311-9 |
17-Hydroxyprogesterone^30M post dose corticotropin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --30 minutes post dose corticotropin |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
101311-9 |
|
|
|
|
Observation |
|
|
|
0 |
17OHP 30M p ACTH SerPl-mCnc |
|
|
|
N |
|
17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17-P; 30M p ACTH; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Hydroxyproges; Hydroxyprogstron; Level; Mass concentration; p ACTH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 101312-7 |
17-Hydroxyprogesterone^1H post dose corticotropin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxyprogesterone [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
101312-7 |
|
|
|
|
Observation |
|
|
|
0 |
17OHP 1h p ACTH SerPl-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17-P; 1h p ACTH; 60 min; 60 minutes; 60M; 60min; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Hydroxyproges; Hydroxyprogstron; Level; Mass concentration; p ACTH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 101313-5 |
17-Hydroxyprogesterone post corticotropin stimulation panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
17-Hydroxyprogesterone post corticotropin stimulation panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
101313-5 |
|
|
|
|
Order |
|
|
|
0 |
17OH-Preg p corticotropin stim pnl SerPl |
|
|
|
N |
|
17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17OH-Preg p corticotropin stim pnl; 17-P; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Hydroxyproges; Hydroxyprogstron; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; PST; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Stim; Tumor marker |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101314-3 |
17-Hydroxypregnenolone & 17-Hydroxyprogesterone post corticotropin stimulation panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
17-Hydroxypregnenolone and 17-Hydroxyprogesterone p corticotropin stim panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
101314-3 |
|
|
|
|
Order |
|
|
|
0 |
17OH-Preg + 17OHP p corticotrop pl SerPl |
|
|
|
N |
|
17 alpha-Hydroxypregnanolone; 17 hydroxy pregnenolone; 17-alpha-Hydroxypregnenolone; 17alpha-Hydroxypregnenolone; 17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17OH-Preg; 17OH-Preg + 17OHP p corticotrop pl; 17OH-Preg p corticotropin stim pnl; 17-P; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Hydroxyproges; Hydroxyprogstron; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; PST; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Stim; Tumor marker |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101315-0 |
Cortisol & Cortisone panel |
- |
Urine |
Pt |
- |
|
|
ACTIVE |
Cortisol and Cortisone panel - Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101315-0 |
|
|
|
|
Order |
|
|
|
0 |
Cortisol + Cortisone panel Ur |
|
|
|
N |
|
11-beta HSD; 11-beta-HSD1; 11-beta-HSD2; 11-beta-hydroxy steroid dehydrogenase; 11-�Ÿ-HSD1; 11-�Ÿ-HSD2; 17-Hydroxycorticosterone; c155; Chemistry; Compound E; Compound F; Coritsol; Cort; Cortisol + Cortisone panel; F; hydrocortisone; Pan; PANEL.CHEMISTRY; Panl; Pnl; Point in time; Random; UA; UR; Urn |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101316-8 |
Cortisol & 17-Hydroxyprogesterone post corticotropin stimulation panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Cortisol and 17-Hydroxyprogesterone post corticotropin stimulation panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHAL |
|
101316-8 |
|
|
|
|
Order |
|
|
|
0 |
F+17-OHP p corticotropin stim pl SerPl |
|
|
|
N |
|
17-alpha-hydroxyprogesterone; 17-Hydroxycorticosterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17OH-Preg p corticotropin stim pnl; 17-P; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Compound F; Coritsol; Cort; Cortrosyn; F; F+17-OHP p corticotropin stim pl; hydrocortisone; Hydroxyproges; Hydroxyprogstron; Pan; PANEL.CHALLENGE; Panl; Pl; Plasma; Plsm; Pnl; Point in time; PST; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Stim; Tumor marker |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101317-6 |
17-Hydroxypregnenolone^30M post dose corticotropin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --30 minutes post dose corticotropin |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
101317-6 |
|
|
|
|
Observation |
|
|
|
0 |
17OH-Preg 30M p ACTH SerPl-mCnc |
|
|
|
N |
|
17 alpha-Hydroxypregnanolone; 17 hydroxy pregnenolone; 17-alpha-Hydroxypregnenolone; 17alpha-Hydroxypregnenolone; 17OH-Preg; 30M p ACTH; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; p ACTH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 101318-4 |
17-Hydroxypregnenolone^1H post dose corticotropin |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxypregnenolone [Mass/volume] in Serum or Plasma --1 hour post dose corticotropin |
|
MIN |
DefinitionDescription |
|
|
ng/dL |
|
|
|
|
|
|
CHAL |
|
101318-4 |
|
|
|
|
Observation |
|
|
|
0 |
17OH-Preg 1h p ACTH SerPl-mCnc |
|
|
|
N |
|
1 hour; 1.0Hr; 17 alpha-Hydroxypregnanolone; 17 hydroxy pregnenolone; 17-alpha-Hydroxypregnenolone; 17alpha-Hydroxypregnenolone; 17OH-Preg; 1h p ACTH; 60 min; 60 minutes; 60M; 60min; ACTH; Adrenocorticotrophic hormone; Adrenocorticotropin; After; c206; c74; CHEMISTRY.CHALLENGE TESTING; Cortrosyn; Level; Mass concentration; p ACTH; p dose; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Rc206; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/dL |
|
|
|
0 |
| 101319-2 |
Cortisol & Cortisone panel |
- |
Urine |
24H |
- |
|
|
ACTIVE |
Cortisol and Cortisone panel - 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
101319-2 |
|
|
|
|
Order |
|
|
|
0 |
Cortisol + Cortisone panel 24h Ur |
|
|
|
N |
|
1 day; 11-beta HSD; 11-beta-HSD1; 11-beta-HSD2; 11-beta-hydroxy steroid dehydrogenase; 11-�Ÿ-HSD1; 11-�Ÿ-HSD2; 17-Hydroxycorticosterone; 24 hours; 24HR; c155; Chemistry; Compound E; Compound F; Coritsol; Cort; Cortisol + Cortisone panel; F; hydrocortisone; Pan; PANEL.CHEMISTRY; Panl; Pnl; UA; UR; Urn |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 10132-9 |
T' wave amplitude.lead AVR |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
T' wave amplitude in lead AVR |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
10132-9 |
|
EKG |
|
|
Observation |
|
|
|
0 |
T' wave Amp L-AVR |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; T prime; T' wave Amp L-AVR; T wave Amp L-AVR; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 101321-8 |
MDS v3.0 - RAI v1.18.11 - Self-Care - Admission Performance |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.18.11 - Self-Care - Admission Performance |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
101321-8 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.78 |
2.74 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
| 101322-6 |
MDS v3.0 - RAI v1.18.11 - Self-Care - Discharge Goal |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.18.11 - Self-Care - Discharge Goal |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
101322-6 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Disch; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.77 |
2.74 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
| 101323-4 |
MDS v3.0 - RAI v1.18.11 - Mobility - Admission Performance |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.18.11 - Mobility - Admission Performance during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
101323-4 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.78 |
2.74 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
| 101324-2 |
MDS v3.0 - RAI v1.18.11 - Mobility - Discharge Goal |
- |
^Patient |
RptPeriod |
- |
CMS Assessment |
|
ACTIVE |
MDS v3.0 - RAI v1.18.11 - Mobility - Discharge Goal during assessment period [CMS Assessment] |
|
PANEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.SURVEY.CMS |
|
101324-2 |
|
CMS Assessment |
|
|
Subset |
|
|
|
0 |
|
|
|
|
N |
|
Centers for Medicare and Medicaid Assessment; Disch; Pan; Panel; PANEL.SURVEY.CMS; Panl; Pnl; Report period; Survey |
2.75 |
2.74 |
|
Organizer |
|
|
|
|
|
|
|
|
|
0 |
